Laurus Labs Pvt Ltd

About the Company :

Incorporated in September 2005, Larus Labs Ltd is promoted by Dr C Satyanarayana, now Chief Executive Officer (CEO) of the company. In FY08, the company entered into a strategic partnership with Aptuit (Singapore) P Ltd. (ASPL), subsidiary of Aptuit Inc. a US based drug development Services Company. Consequent to the strategic partnership, the name of the company was changed to Aptuit Laurus P Ltd. effective July 2007.

In February 2012, ASPL sold 32% of its stake in LLL to Fidelity Growth Partners India (FGPI). Consequent to the stake sale, the company has been renamed to Laurus Labs Pvt. Ltd. During October 2014, Warburg Pincus has also acquired part stakes held by Fidelity and a few other promoter associates. Further in August 2016, name of the company is changed to Laurus Labs Limited and subsequently in the month of December 2016, the company got listed on BSE and NSE. The company is primarily engaged in research and development with a strong presence in anti-retroviral (ARV), oncology and hepatitis therapeutic segments. The company is also into manufacturing of APIs in Oncology and other therapeutic segments and is one of the leading suppliers of APIs in the ARV therapeutic segment. Headquartered in Hyderabad, Telangana, the company has manufacturing facilities in Visakhapatnam, Andhra Pradesh and R&D centre in Hyderabad, Telangana. LLL has acquired 100% stake in one of the group companies, Sriam Labs Limited (SLL) as on November 01, 2016 at a consideration price of Rs. 20.99 crore.

In October 2017, the company is planning to invest Rs. 3000 million to set up facilities to manufacture formulations at its Vizag plant